small molecule

KERENDIA

FINERENONE

Loss of exclusivityJuly 2035latest FDA-listed patent expiry

CompanyBayer Healthcare →View the full company profile on CliffBio

Drug detail

Brand name	KERENDIA
Active ingredient	FINERENONE
Strength	20MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	July 2021
Marketing status	RX

Listed patents

Patent	Expires	Type
RE49826	July 2035	substance
8436180	August 2033	substance, product

Regulatory exclusivity

Code	Expires
I-970	July 2028
NCE	July 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Bayer Healthcare